Repligen Corporation (NASDAQ: RGEN) and Mallinckrodt PLC (NYSE:MNK) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, dividends, institutional ownership, earnings, profitability, valuation and risk.

Insider and Institutional Ownership

97.9% of Repligen Corporation shares are owned by institutional investors. Comparatively, 97.7% of Mallinckrodt PLC shares are owned by institutional investors. 1.5% of Repligen Corporation shares are owned by company insiders. Comparatively, 0.8% of Mallinckrodt PLC shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Analyst Ratings

This is a breakdown of current ratings and price targets for Repligen Corporation and Mallinckrodt PLC, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Repligen Corporation 0 1 3 0 2.75
Mallinckrodt PLC 0 4 13 0 2.76

Repligen Corporation presently has a consensus target price of $46.00, indicating a potential upside of 19.51%. Mallinckrodt PLC has a consensus target price of $59.97, indicating a potential upside of 96.82%. Given Mallinckrodt PLC’s stronger consensus rating and higher probable upside, analysts clearly believe Mallinckrodt PLC is more favorable than Repligen Corporation.

Earnings and Valuation

This table compares Repligen Corporation and Mallinckrodt PLC’s revenue, earnings per share and valuation.

Gross Revenue Price/Sales Ratio NetIncome Earnings Per Share Price/Earnings Ratio
Repligen Corporation $104.54 12.55 $11.68 $0.51 75.47
Mallinckrodt PLC $829.90 3.65 -$153.20 $4.10 7.43

Repligen Corporation has higher revenue, but lower earnings than Mallinckrodt PLC. Mallinckrodt PLC is trading at a lower price-to-earnings ratio than Repligen Corporation, indicating that it is currently the more affordable of the two stocks.

Profitability

This table compares Repligen Corporation and Mallinckrodt PLC’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Repligen Corporation 15.61% 9.90% 5.93%
Mallinckrodt PLC 12.64% 15.28% 5.20%

Risk and Volatility

Repligen Corporation has a beta of 1.05, suggesting that its share price is 5% more volatile than the S&P 500. Comparatively, Mallinckrodt PLC has a beta of 1.46, suggesting that its share price is 46% more volatile than the S&P 500.

About Repligen Corporation

Repligen Corporation is a bioprocessing company. The Company is focused on the development, manufacture and commercialization of products used to improve the interconnected phases of the biological drug manufacturing process. The Company’s portfolio includes protein products, chromatography products, and filtration products. It provides Protein A ligands, a component of Protein A chromatography resins (media) used in the purification of virtually all monoclonal antibody (mAb)-based drugs on the market or in development. Its chromatography portfolio includes various products used in the downstream purification and quality control of biological drugs. Its OPUS pre-packed chromatography columns (PPCs) are used in the purification of clinical-stage biologics. Its filtration products include XCell Alternating Tangential Flow (ATF) Systems and Sius tangential flow filtration (TFF) cassettes. Sius TFF cassettes are used to concentrate clinical and commercial-stage biologic drugs.

About Mallinckrodt PLC

Mallinckrodt public limited company develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and hemostasis products, and central nervous system drugs. Its segments include Specialty Brands and Specialty Generics. The Specialty Brands segment produces and markets branded pharmaceutical products and therapies. The Specialty Generics segment produces and markets specialty generic pharmaceuticals and active pharmaceutical ingredient (API) consisting of biologics, medicinal opioids, synthetic controlled substances, acetaminophen and other active ingredients. Its product portfolio includes Acthar, Inomax, Ofirmev, Therakos immunotherapy, Hemostasis products and StrataGraft.

Receive News & Ratings for Repligen Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Repligen Corporation and related companies with Analyst Ratings Network's FREE daily email newsletter.